Transcatheter tricuspid valve intervention (TTVI) improved activity in fragile patients with chronic HF, according to findings published in the European Journal of Heart Failure. The trial of patients with HF and severe tricuspid regurgitation (TR) indicated that the effect of TTVI was significantly higher in advanced HF with low baseline activity (baseline continuous physical activity [CPA], <1,350 steps/ day; 1-year CPA increase: +121.3%) compared with moderate activity (baseline CPA, 1,350- 4,959 steps/day; 1-year CPA increase: +27.5%) or high activity (baseline CPA, >4,959 steps/ day; 1-year CPA change: +2.6%).
